Compile Data Set for Download or QSAR
maximum 50k data
Found 108 Enz. Inhib. hit(s) with all data for entry = 1242
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313715(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  3.10nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313704(US10167280, Example 21 | US10167280, Example 44 | ...)
Affinity DataIC50:  4nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313714(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  4.30nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313723(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  4.60nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313714(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  4.60nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313715(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  5.10nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313721(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  5.60nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313719(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  5.70nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313704(US10167280, Example 21 | US10167280, Example 44 | ...)
Affinity DataIC50:  5.80nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313712(US10167280, Example 17 | US10167280, Example 22)
Affinity DataIC50:  6nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313703(US10167280, Example 8)
Affinity DataIC50:  6nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313719(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  6.20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313721(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  6.20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313712(US10167280, Example 17 | US10167280, Example 22)
Affinity DataIC50:  6.5nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313721(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  6.90nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313701(US10167280, Example 23 | US10167280, Example 6)
Affinity DataIC50:  7nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313701(US10167280, Example 23 | US10167280, Example 6)
Affinity DataIC50:  7.10nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313719(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  7.40nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313721(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  8nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313704(US10167280, Example 21 | US10167280, Example 44 | ...)
Affinity DataIC50:  8nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313724(5-({2-[4-(2-Cyano-5-methylphenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  8.20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313723(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  8.60nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313719(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  8.60nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313704(US10167280, Example 21 | US10167280, Example 44 | ...)
Affinity DataIC50:  9nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313724(5-({2-[4-(2-Cyano-5-methylphenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  10nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313703(US10167280, Example 8)
Affinity DataIC50:  11nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313726(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  11nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313727(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  11nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313727(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  12nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313700(US10167280, Example 5)
Affinity DataIC50:  12nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313728(5-({2-[4-(2-Cyano-5-methylphenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  14nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313732(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  14nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313731(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  14nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313733(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  16nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313697(US10167280, Example 2)
Affinity DataIC50:  16nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313699(US10167280, Example 4)
Affinity DataIC50:  16nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313725(5-({2-[4-(2-Cyano-5-methylphenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  17nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313728(5-({2-[4-(2-Cyano-5-methylphenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  19nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313730(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  19nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313731(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  19nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313697(US10167280, Example 2)
Affinity DataIC50:  20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313725(5-({2-[4-(2-Cyano-5-methylphenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313696(US10167280, Example 1)
Affinity DataIC50:  20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313701(US10167280, Example 23 | US10167280, Example 6)
Affinity DataIC50:  20nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313712(US10167280, Example 17 | US10167280, Example 22)
Affinity DataIC50:  22nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313696(US10167280, Example 1)
Affinity DataIC50:  22nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313701(US10167280, Example 23 | US10167280, Example 6)
Affinity DataIC50:  22nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313735(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  23nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313733(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  23nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM313732(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  23nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 108 total ) | Next | Last >>
Jump to: